Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
IgA nephropathy is the most common primary glomerulonephritis worldwide and has a highly variable clinical course, making early prognostication challenging. It is increasingly recognised that few patients will avoid kidney failure in their lifetime. Although risk factors such as proteinuria and baseline kidney function are linked to outcomes, their predictive value for individuals remains limited. Understanding disease trajectories in real-world cohorts is crucial to improve risk stratification and guide targeted, personalised interventions and enrich trial recruitment.
This study was conducted at a metropolitan tertiary centre in Brisbane, Australia. All patients known to the Kidney Health service with a biopsy proven IgA nephropathy from January 2010 – August 2025 were included for analysis. Additional cases were identified by screening hospital admissions for relevant ICD-10 codes (e.g. N02.8: recurrent/persistent haematuria/IgA nephropathy; D69.0: Henoch–Schönlein purpura), followed by review of kidney biopsy.
A total of 153 patients met inclusion criteria; 100 (65%) were male. At diagnosis, the median age was 43 years (IQR 33.8–60.3), median eGFR was 52 mL/min/1.73 m² (IQR 27.5-87), and median proteinuria was 1.95 g/24 h (IQR 0.77-3.73). The mean follow-up duration was 60.7 months (median 47.4, IQR 23.0–89.1).
Among 88 patients with ≥3 years of follow-up, the overall mean change eGFR slope was –2.12 mL/min/1.73 m²/year. Patients with <1 g/day proteinuria (n = 29) had a mean change in slope of –2.09 mL/min/1.73 m²/year (95% CI –4.31 to 0.13), while those with >1 g/day proteinuria (n = 55) had a mean slope of –2.62 mL/min/1.73 m²/year (95% CI –4.18 to –1.07); There was no statistically significant difference between these groups (Welch’s t-test: p = 0.691).
Within the cohort with >1 g/day proteinuria, 27 patients treated with immunosuppression had available 3-year eGFR data. Their mean baseline eGFR was 61.7 mL/min/1.73 m² (95% CI 51.6–71.9), and their mean slope was –3.02 mL/min/1.73 m²/year (95% CI –4.71 to –1.34). In comparison, 28 patients who did not receive immunosuppression had a mean baseline eGFR of 60.0 mL/min/1.73 m² (95% CI 49.3–70.3) and a slope of –2.24 mL/min/1.73 m²/year (95% CI –4.93 to 0.46). The difference between treated and untreated groups was not statistically significant (Welch’s t-test: p = 0.62).
Overall, 43 of 153 patients (28%) experienced >50% eGFR decline during follow-up, with a median time to event of 31.3 months; 24 of 153 patients (16%) had documented clinical features of IgA vasculitis, 6 (25%) of whom experienced >50% eGFR decline during follow-up, with a mean time to event of 37.9 months. Male patients were more likely to experience event (35% vs 15%; RR 2.32, 95% CI 1.16-4.64; p=0.009).
IgA nephropathy remains an aggressive disease with considerable impact on health of people living with the disease in Australia. Despite a significant proportion of patients experiencing decline in kidney function, baseline proteinuria or eGFR does not reliably distinguish those with rapid progression. These results highlight the limitations proteinuria as a predictor of clinical outcome in real-world practice and underscore the need for improved risk stratification strategies to identify high-risk patients and optimise early intervention.
